Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Scolding

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Practical Neurology|June 24, 2015
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosisNeil Scolding, David Barnes, Sarah Cader, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Lancet (London, England)|May 22, 2007
Medical training in the UK: sleepwalking to disasterMorris Brown, Nick Boon, Nick Brooks, et al.
Multiple Sclerosis and Related Disorders|May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
BMJ Open|February 5, 2024
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, Jennifer Petrie, Kate E M Duffy, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Practical Neurology|June 24, 2015
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosisNeil Scolding, David Barnes, Sarah Cader, et al.
BMJ Open|November 26, 2021
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosisRuth Dobson, Matthew Craner, Ed Waddingham, et al.
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Lancet (London, England)|May 22, 2007
Medical training in the UK: sleepwalking to disasterMorris Brown, Nick Boon, Nick Brooks, et al.
Multiple Sclerosis and Related Disorders|May 31, 2022
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)Ruth Dobson, Matthew Craner, Ed Waddingham, et al.
BMJ Open|February 5, 2024
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, Jennifer Petrie, Kate E M Duffy, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Pageof 7